Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer

Jaguar Health, Inc.

All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.
Initial proof-of-concept data: crofelemer reduced TPN up to 27% in MVID patient and up to 12.5% in SBS-IF patient.
FDA meeting aligned on regulatory pathway to complete supplemental NDA for crofelemer in metastatic breast cancer (orphan population).
Company plans to seek license partnerships for orphan indications to generate non-dilutive funding.

item 5.07item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.